Objective: This study aims to reveal clinical, hormonal and ultrasound imaging features of patients treated with leuprolide acetate for diagnosis of precoccious puberty.
Design: Retrospective analysis of patients with a diagnosis of central precoccious puberty and treated with leuprolide acetate between January 2008 and January 2013.
Patients: 81 girls and two boys with early signs of puberty.
Results: There was a positive correlation between basal LH and peak LH/FSH values. An organic etiology was revealed in 14.8% of girl patients (hydrocephaly (7), meningomyelocele (2), hypophyseal tumor (2), rathke cleft cyst (1), and 50% of boys hamartoma (1)). The 50% of girls with organic etiology was >6 years. Majority of the patients were between 6 and 8 years old and idiopathic cases. Organic etiologies also can be seen in children older than 6 years old age, so kranial MR imaging may be indicated for selective cases >6 years old children (Table 1).
|Mean age of first sign of puberty (years)||6.66±1.87|
|Mean age of initiation of leuprolide acetate (years)||7.78±1.82|
|Time to treatment (months)||13.80±11.5|
|Predicted adult height||−0.86±1.46|
|Tanner stage at the initiation of treatment||stage 2: 6 (7.3%); stage 3: 32 (39%); stage 4: 37 (45.1%); stage 5: 7(8.5%)|
|Mean uterine length on USG (mm)||37.02±11.07|
|Mean ovary volüme (ml)||2.89±2.22|
|Mean basal LH (mIU/ml)||1.61±1.9|
|Mean peak LH on LHRH analog test (mIU/ml)||12.46 (72% >5 mIU/ml)|
|Pubertal LH/FSH (>0.66) (%)||42%|
|Mean bone age (years)||9.78±2.22|
20 - 22 Sep 2014
European Society for Paediatric Endocrinology